breast cancer

Research in Review

Recurrence Score Assay Helping to Guide Breast Cancer Decision Making

10/26/2016

JCP Editors

Use of the 21-gene recurrence score (RS) assay is helping clinicians and patients decide which treatments are best for them, according to a large-scale survey of more than 3000 women treated for breast...

Use of...

10/26/2016

Journal of Clinical Pathways

Quiz

Friday Morning Quiz: Week of October 9-15

10/13/2016

JCP Editors

Which of the following drugs added to adjuvant endocrine therapy helped to reduce the risk for contralateral breast cancer in women with invasive breast...

Which...

10/13/2016

Journal of Clinical Pathways

Research in Review

Response-Guided Neoadjuvant Chemotherapy Cost Effective for Breast Cancer

09/07/2016

JCP Editors

Response-guided neoadjuvant chemotherapy (RG-NACT) is more cost effective than conventional NACT for estrogen receptor (ER)-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer, according...

...

09/07/2016

Journal of Clinical Pathways

Research in Review

Factors Affecting 30-Day Mortality in Women With Breast and Lung Cancer

09/04/2016

JCP Editors

Researchers have identified several factors that may affect the risk of early mortality among patients with breast and lung cancer, according to a recent study. In a study published in The Lancet Oncology,...

...

09/04/2016

Journal of Clinical Pathways

Research in Review

Breast Conservation Therapy at Community Settings Leads to Higher Survival Rates than the National Average

09/02/2016

JCP Editors

Breast conservation treatment may led to longer overall survival than other treatment methods for early stage breast cancer, according to a study published in The Journal of Community and Supportive Oncology....

Breast...

09/02/2016

Journal of Clinical Pathways

Research in Review

70-Gene Signature Aids Breast Cancer Decision-Making

08/30/2016

JCP Editors

The 70-gene signature test may help patients with early-stage breast cancer avoid unneeded chemotherapy, according to the results of a study published in The New England Journal of Medicine. The 70-gene signature...

The...

08/30/2016

Journal of Clinical Pathways

Research in Review

Breast Cancer Genes Associated With Increased Risk of Death

08/27/2016

JCP Editors

Two genes in breast cancer tumors may indicate an increased risk of death, suggests a new study published in Oncotarget. For the study, researchers led by Paul H Huang,  looked at breast cancer cells positive...

Two...

08/27/2016

Journal of Clinical Pathways

Research in Review

ESR1 Mutations May Affect Treatment for Metastatic Breast Cancer

08/16/2016

JCP Editors

Estrogen receptor α (ESR1) mutations are highly prevalent in women receiving aromatase inhibitors for metastatic breast cancer (MBC), according to a secondary analysis from a clinical trial. ESR1 mutations found in...

...

08/16/2016

Journal of Clinical Pathways

Research in Review

Aromatase Inhibitor-Treated Patients With Breast Cancer Lacking Necessary Testing

07/19/2016

JCP Editors

Older women most at risk for bone fractures may not be receiving recommended bone density assessments prior to receiving aromatase inhibitor (AI) treatment for breast cancer, according to a study published in the...

Older...

07/19/2016

Journal of Clinical Pathways

Clinical Insights

Yttrium-90 Radioembolization of Nonconventional Liver Tumors

07/18/2016

Jonathan K. Park, MD^1,2; Win Phyu²; Taryar Zaw³; Matthew Walsworth, MD^1,2; Hsin-Yi Lee, MD^1,2; Edward Wolfgang Lee, MD, PhD²

From the ¹Division of Interventional Radiology, Department of Radiology, West Los Angeles VA Medical Center, Los Angeles, California, the ²Division of Interventional Radiology, Department of Radiology, UCLA Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, California, and the ³Department of Radiology, Virginia Commonwealth University, Richmond, Virginia.

Jonathan K. Park, MD1,2; Win Phyu2; T...

Abstract: Yttrium-90 selective internal radiation therapy (SIRT) is a treatment modality used for unresectable hepatic neoplasm, typically from primary hepatic malignancy such as hepatocellular carcinoma or colorectal and neuroendocrine...

Abstract: Yttrium-90 selective...

07/18/2016

IO Learning